CLEC9A binding agents
AssigneesOrionis Biosciences BV, Vib Vzw, Universiteit Gent
InventorsJan Tavernier, Nikolai Kley, Anje Cauwels, Sarah Gerlo
Life of this patent
Estimating the term…
Abstract
The present invention relates, in part, to agents that bind C-type lectin domain containing 9A (Clec9A) and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the Clec9A binding agents and their use in the treatment of various diseases.
Claims11
A composition comprising a targeting moiety that comprises a recognition domain that recognizes and binds to C-type lectin domain family 9 member A (Clec9A), wherein the targeting moiety comprises three complementarity determining regions (CDR1, CDR2, and CDR3) wherein:
- (a) CDR1 comprises an amino acid sequence selected from any one of SEQ ID NOs:
- 2-21, and GSSDSINAMG (SEQ ID NO:
- 324);
- (b) CDR2 comprises an amino acid sequence selected from any one of SEQ ID NOs:
- 22-43;
- and
- (c) CDR3 comprises an amino acid sequence selected from any one of SEQ ID NOs:
- 44-58, LGR, and VIK.
Dependencies are inferred from the claim text.